Refine
Language
- English (83)
Has Fulltext
- yes (83)
Is part of the Bibliography
- no (83)
Keywords
Institute
The European and Mediterranean Plant Protection Organisation (EPPO) is an intergovernmental organization responsible for cooperation in plant protection in the European and Mediterranean region. It provides global distribution maps of pests, and intends to identify the areas at risk from new and emerging pests, in the framework of Pest Risk Analyses. EPPO has developed a decision-support scheme for Pest Risk Analysis (DSS) and a computer program (CAPRA) to assist pest risk analysts in running the decisionsupport scheme. Dedicated rating guidance and a Climatic Suitability Risk Mapping Decision-Support Scheme have recently been developed to guide assessors in identifying the potential area of establishment of a pest. All these tools have been developed taking into account both pest risk science available and needs of policy makers. The use of these tools and of mapping software are undertaken within the framework of EPPO Pest Risk Analyses, as illustrated through the examples of Thaumatotibia leucotreta (Lepidoptera) and Apriona germari (Coleoptera).
Economic globalization depends on the movement of people and goods between countries. As these exchanges increase, so does the potential for translocation of harmful pests, weeds, and pathogens capable of impacting our crops, livestock and natural resources (Hulme 2009), with concomitant impacts on global food security (Cook et al. 2011).
Endothelial to mesenchymal transition in cardiovascular disease : JACC state-of-the-art review
(2019)
Endothelial to mesenchymal transition (EndMT) is a process whereby an endothelial cell undergoes a series of molecular events that lead to a change in phenotype toward a mesenchymal cell (e.g., myofibroblast, smooth muscle cell). EndMT plays a fundamental role during development, and mounting evidence indicates that EndMT is involved in adult cardiovascular diseases (CVDs), including atherosclerosis, pulmonary hypertension, valvular disease, and fibroelastosis. Therefore, the targeting of EndMT may hold therapeutic promise for treating CVD. However, the field faces a number of challenges, including the lack of a precise functional and molecular definition, a lack of understanding of the causative pathological role of EndMT in CVDs (versus being a “bystander-phenomenon”), and a lack of robust human data corroborating the extent and causality of EndMT in adult CVDs. Here, we review this emerging but exciting field, and propose a framework for its systematic advancement at the molecular and translational levels.